We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Chemomab Therapeutics Ltd | NASDAQ:CMMB | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.016 | 1.65% | 0.9849 | 0.87 | 1.34 | 0.9849 | 0.93 | 0.93 | 24,519 | 05:00:02 |
From Jul 2021 to Jul 2024
TEL AVIV, Israel, Feb. 10, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that it will present a company overview at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 9:00 am ET.
To access the event: click https://us02web.zoom.us/j/86168915443
A copy of Chemomab's presentation will also be available on Chemomab's website at https://investors.chemomab.com/ starting on February 24, 2022.
For additional information on accessing the Chemomab presentation, click on Aegis Virtual Conference Calendar.
About Chemomab Therapeutics Ltd.
Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in two Phase 2 safety and efficacy trials—one in patients with primary sclerosing cholangitis and the second in patients with liver fibrosis, with a third Phase 2 trial in systemic sclerosis expected to begin early in 2022. For more information on Chemomab, visit chemomab.com.
Contacts:
Investor Relations:
Irina Koffler
LifeSci Advisors, LLC
Phone: +1-917-734-7387
ir@chemomab.com
Media:
Barbara Lindheim
Chemomab Therapeutics
Consulting Vice President
Investor & Public Relations, Strategic Communications
Phone: +1-917-355-9234
barbara@chemomab.com
View original content:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-present-at-aegis-virtual-conference-301479592.html
SOURCE Chemomab Therapeutics Ltd
Copyright 2022 PR Newswire
1 Year Chemomab Therapeutics Chart |
1 Month Chemomab Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
